GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Egyptian International Pharmaceutical Investments (CAI:PHAR) » Definitions » 5-Year Yield-on-Cost %

Egyptian International Pharmaceutical Investments (CAI:PHAR) 5-Year Yield-on-Cost % : 3.09 (As of May. 06, 2024)


View and export this data going back to 1995. Start your Free Trial

What is Egyptian International Pharmaceutical Investments 5-Year Yield-on-Cost %?

Egyptian International Pharmaceutical Investments's yield on cost for the quarter that ended in Dec. 2023 was 3.09.


The historical rank and industry rank for Egyptian International Pharmaceutical Investments's 5-Year Yield-on-Cost % or its related term are showing as below:

CAI:PHAR' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.29   Med: 2.85   Max: 5.93
Current: 3.09


During the past 13 years, Egyptian International Pharmaceutical Investments's highest Yield on Cost was 5.93. The lowest was 1.29. And the median was 2.85.


CAI:PHAR's 5-Year Yield-on-Cost % is ranked better than
62.4% of 500 companies
in the Drug Manufacturers industry
Industry Median: 2.155 vs CAI:PHAR: 3.09

Competitive Comparison of Egyptian International Pharmaceutical Investments's 5-Year Yield-on-Cost %

For the Drug Manufacturers - Specialty & Generic subindustry, Egyptian International Pharmaceutical Investments's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Egyptian International Pharmaceutical Investments's 5-Year Yield-on-Cost % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Egyptian International Pharmaceutical Investments's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Egyptian International Pharmaceutical Investments's 5-Year Yield-on-Cost % falls into.



Egyptian International Pharmaceutical Investments 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Egyptian International Pharmaceutical Investments is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

Egyptian International Pharmaceutical Investments  (CAI:PHAR) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Egyptian International Pharmaceutical Investments 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Egyptian International Pharmaceutical Investments's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


Egyptian International Pharmaceutical Investments (CAI:PHAR) Business Description

Traded in Other Exchanges
N/A
Address
1st Industrial Zone B1, EIPICO, 10th of Ramadan, EGY
Egyptian International Pharmaceutical Investments is an Egypt based company pharmaceutical generic drugs. It holds license agreements with a group of pharmaceutical companies to produce their products locally and replace the imported ones. The company produces dosage forms, Spansule capsules, non-traditional dosage forms including soft gelatin capsules, lyophilized products, gels, sprayers and effervescent tablets. It exports its products to Arab countries, African, Asian and East European Countries. Its products portfolio includes antibiotics, anesthetics, analgesics, antihypertensives, cholesterol-lowering medications, ophthalmic products, blood substitutes and restoratives, dermatological drugs and vitamins. Some of its products are Vasotec, Co-vasotec, Flumox, and Cefotax.